Adaptive Randomized study of idarubicin and cytarabine (IA) alone or with interleukin 11 (IL-11) as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS).

被引：0
|
作者：
Giles, F [1 ]
Kantarjian, H [1 ]
Cortes, J [1 ]
Tsimberidou, A [1 ]
Faderl, S [1 ]
Verstovsek, S [1 ]
Thomas, D [1 ]
Garcia-Manero, G [1 ]
Wierda, W [1 ]
Ferrajoli, A [1 ]
Kornblau, S [1 ]
Andreeff, M [1 ]
O'Brien, S [1 ]
Beran, M [1 ]
Estey, E [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4740
引用
收藏
页码：253B / 253B
页数：1
相关论文
共 50 条
  • [1] Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
    Giles, FJ
    Kantarjian, HM
    Cortes, JE
    Faderl, S
    Verstovsek, S
    Thomas, D
    Garcia-Manero, G
    Wierda, W
    Ferrajoli, A
    Kornblau, S
    Mattiuzzi, GN
    Tsimberidou, AM
    Albitar, M
    O'Brien, SM
    Estey, E
    LEUKEMIA RESEARCH, 2005, 29 (06) : 649 - 652
  • [2] Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome
    Shadman, Mazyar
    Mawad, Raya
    Dean, Carol
    Chen, Tara L.
    Shannon-Dorcy, Kathleen
    Sandhu, Vicky
    Hendrie, Paul C.
    Scott, Bart L.
    Walter, Rol B.
    Becker, Pamela S.
    Pagel, John M.
    Estey, Elihu H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : 483 - 486
  • [3] Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Shadman, Mazyar
    Mawad, Raya
    Dean, Carol
    Shannon-Dorcy, Kathleen
    Sandhu, Vicky
    Hendrie, Paul C.
    Scott, Bart L.
    Walter, Roland B.
    Becker, Pamela S.
    Pagel, John
    Estey, Elihu H.
    BLOOD, 2014, 124 (21)
  • [4] Adaptive randomization of idarubicin and Ara-C (IA) ± interleukin (IL11) in patients with newly diagnosed (ND) acute Myelogenous leukemia (AML) or high-risk Myelodysplastic syndrome (MDS)
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    O'Brien, S
    Kantarjian, R
    Giles, F
    BLOOD, 2002, 100 (11) : 264B - 264B
  • [5] Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Reville, Patrick K.
    Kantarjian, Hagop
    Borthakur, Gautam
    Yilmaz, Musa
    Daver, Naval
    Short, Nicholas
    DiNardo, Courtney D.
    Kornblau, Steven M.
    Pemmaraju, Naveen
    Jain, Nitin
    Alvarado, Yesid
    Bose, Prithviraj
    Jabbour, Elias
    Chien, Kelly S.
    Abbas, Hussein A.
    Masarova, Lucia
    Wang, Sa A.
    Tidwell, Rebecca S. S.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2022, 140 : 1702 - 1704
  • [6] Effect of hematologic improvement (HI) on survival in patients (pts) given targeted therapy (TT) as initial treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS)
    Yanada, M.
    Huang, X.
    O'Brien, S.
    Garcia-Manero, G.
    Ravandi, F.
    Borthakur, G.
    Issa, J.
    Giles, F.
    Kantarjian, H.
    Estey, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality
    Walter, Roland B.
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Becker, Pamela S.
    Hendrie, Paul C.
    Ostronoff, Fabiana
    Ranker, Elizabeth M.
    Othus, Megan
    Louie, Arthur C.
    Estey, Elihu H.
    BLOOD, 2014, 124 (21)
  • [8] Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML)
    Jabbour, E.
    Faderl, S.
    Ravandi, F.
    Konopleva, M.
    Verstovsek, S.
    Cortes, J.
    Wierda, W.
    Newsome, W. M.
    Yang, H.
    Kantarjian, H.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Assi, Rita
    Kantarjian, Hagop M.
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Benton, Christopher B.
    Thompson, Philip A.
    Borthakur, Gautam
    Kadia, Tapan M.
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina Y.
    Takahashi, Koichi
    Kornblau, Steven M.
    DiNardo, Courtney D.
    Estrov, Zeev E.
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James P.
    Sharma, Padmanee
    Pierce, Sherry A.
    Pike, Allison
    Cortes, Jorge E.
    Ravandi, Farhad
    BLOOD, 2018, 132
  • [10] The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)
    Zeidan, Amer M.
    Esteve, Jordi
    Giagounidis, Aristoteles
    Kim, Hee-Je
    Miyazaki, Yasushi
    Platzbecker, Uwe
    Schuh, Andre C.
    Sekeres, Mikkael A.
    Westermann, Jorg
    Xiao, Zhijian
    Malek, Kamel
    Scott, Jeffrey
    Niolat, Julie
    Peyrard, Severine
    Ma, Fei
    Kiertsman, Flavia
    Stegert, Mario
    Hertle, Sabine
    Fenaux, Pierre
    Santini, Valeria
    BLOOD, 2020, 136
12345